|
The Neurotechnology Industry 2007 Report
published May 17, 2007
Drugs, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets
Now in its third year, The Neurotechnology Industry 2007 Report is a completely updated 350-page report. It is the only publication to provide a unified market-based framework to help investors, companies and entrepreneurs easily quantify opportunities, determine risks and understand the dynamics of rapidly changing neurotech markets.
The report tracks advances in 15 indications at 500 companies including Alzheimer’s, addiction, anxiety, depression, epilepsy, mild cognitive impairment, obesity, pain, Parkinson’s, schizophrenia, sensory disorders, sleep disorders, and stroke.
Contact us for bulk, academic, and nonprofit discounts
|
"The Neurotech Industry Report provides the first comprehensive view of drugs, devices and diagnostics for the brain and nervous system. It is a must read for any investor or executive in the industry."
Roger Quy, PhD, General Partner, Technology Partners
"A penetrating analysis of the complex industry that is bringing us new treatments for the brain and the mind.”
Samuel Barondes, PhD, Director, Center for Neurobiology and Psychiatry, UCSF
"Neurotech companies are addressing the largest and fastest growing unmet medical market and the potential for high return investment has never been more compelling.”
Mark Cochran, CEO, Blanchett Rockefeller Neuroscience Institute and Managing Director, NeuroVentures Capital
“Finally a complete view of companies, technologies and global trends driving neurotechnology. The Neurotechnology Industry Report fills a big gap that traditional CNS market and investment reports miss."
Global Healthcare Group, Major Investment Bank
|
|
